154 related articles for article (PubMed ID: 11456567)
1. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.
Duncan SJ; Grüschow S; Williams DH; McNicholas C; Purewal R; Hajek M; Gerlitz M; Martin S; Wrigley SK; Moore M
J Am Chem Soc; 2001 Jan; 123(4):554-60. PubMed ID: 11456567
[TBL] [Abstract][Full Text] [Related]
2. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
Clark RC; Lee SY; Searcey M; Boger DL
Nat Prod Rep; 2009 Apr; 26(4):465-77. PubMed ID: 19642417
[TBL] [Abstract][Full Text] [Related]
3. Binding of an inhibitor of the p53/MDM2 interaction to MDM2.
Duncan SJ; Cooper MA; Williams DH
Chem Commun (Camb); 2003 Feb; (3):316-7. PubMed ID: 12613590
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.
Cominetti MMD; Goffin SA; Raffel E; Turner KD; Ramoutar JC; O'Connell MA; Howell LA; Searcey M
Bioorg Med Chem Lett; 2015 Nov; 25(21):4878-4880. PubMed ID: 26115576
[TBL] [Abstract][Full Text] [Related]
5. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
[TBL] [Abstract][Full Text] [Related]
6. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
9. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
10. Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions.
Malkinson JP; Zloh M; Kadom M; Errington R; Smith PJ; Searcey M
Org Lett; 2003 Dec; 5(26):5051-4. PubMed ID: 14682762
[TBL] [Abstract][Full Text] [Related]
11. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
Chène P
Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
[TBL] [Abstract][Full Text] [Related]
13. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
Zheleva DI; Lane DP; Fischer PM
Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
15. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
Galatin PS; Abraham DJ
Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
[TBL] [Abstract][Full Text] [Related]
16. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
[No Abstract] [Full Text] [Related]
18. Small molecule inhibitors of p53/MDM2 interaction.
Fotouhi N; Graves B
Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
[TBL] [Abstract][Full Text] [Related]
19. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
[TBL] [Abstract][Full Text] [Related]
20. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction.
Fasan R; Dias RL; Moehle K; Zerbe O; Vrijbloed JW; Obrecht D; Robinson JA
Angew Chem Int Ed Engl; 2004 Apr; 43(16):2109-12. PubMed ID: 15083458
[No Abstract] [Full Text] [Related]
[Next] [New Search]
